Latest1 information on COVID-19
©2022 Stanford Medicine
Trial ID: NCT01987375
Phase I, Open-label Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cetuximab-IRDye800 as an Optical Imaging Agent to Detect Cancer During Surgical Procedures
Associate Professor of Otolaryngology - Head & Neck Surgery (OHNS)
Clinical Associate Professor, Otolaryngology (Head and Neck Surgery)
Edward C. and Amy H. Sewall Professor in the School of Medicine and Professor, by courtesy, of Dermatology
1. Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck.
2. Patients diagnosed with any T stage, any subsite within the head and neck that are
scheduled to undergo surgical resection. Patients with recurrent disease or a new
primary will be allowed.
3. Planned standard of care surgery with curative intent for squamous cell carcinoma
4. Age ≥ 19 years
5. Have life expectancy of more than 12 weeks
6. Karnofsky performance status of at least 70% or ECOG/Zubrod level 1
7. Have acceptable hematologic status, coagulation status, kidney function, and liver
function including the following clinical results:
- Hemoglobin ≥ 9gm/dL
- Platelet count ≥ 100,000/mm3
- Magnesium, potassium and calcium greater than or equal than the lower limit of
normal range per institution normal lab values
- TSH <10 micro International Units/mL
1. Received an investigational drug within 30 days prior to first dose of
2. Had within 6 months prior to enrollment: MI, CVA, uncontrolled CHF, significant liver
disease, unstable angina
3. Inadequately controlled hypertension with or without current antihypertensive
4. History of infusion reactions to cetuximab or other monoclonal antibody therapies.
5. Women who are pregnant or breast feeding
6. Patients who have a grade 2 or greater reaction with the test/loading cetuximab dose.
7. Evidence of QT prolongation on pretreatment ECG (greater than 440 ms in males or
greater than 450 ms in females).
8. Lab values that in the opinion of the primary surgeon would prevent surgical
9. Patients receiving Class IA (quinidine, procanamide) or Class III (dofetilide,
amiodarone, sotalol) antiarrhythmic agents.
10. Patients with TSH>11
School of Medicine
300 Pasteur Drive
Stanford, CA 94305